163
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China

, , & ORCID Icon
Pages 4625-4634 | Published online: 03 May 2022

References

  • Wang D, Zhao C, Fu L, Liu Y, Zhang W, Xu T. Primary Clear Cell Adenocarcinoma of the Cervix: a Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol. Obstet Gynecol Int. 2019;2019:9465375. doi:10.1155/2019/9465375
  • Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284(15):878–881.
  • Liu Z, Li J, Gu H, Tu H, Liu G, Liu J. Clear Cell Adenocarcinoma of Uterine Cervix: a Single Institution Retrospective Experience. Front Oncol. 2020;10:532748.
  • Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol. 2011;121(1):32–42.
  • Pirog EC, Lloveras B, Molijn A, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathol. 2014;27(12):1559–1567.
  • Yang L, Zheng A, Zhang X, Fang X, Sun W, Chen Y. Clear Cell Carcinoma of the Uterine Cervix: a Clinical and Pathological Analysis of 47 Patients Without Intrauterine Diethylstilbestrol Exposure. Int j Gynecol Cancer. 2017;27(5):1009–1014.
  • Shimada M, Nishimura R, Nogawa T, et al. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. Mol Clin Oncol. 2013;1(4):780–784.
  • Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R. Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol. Gynecol Oncol. 2000;76(3):331–335.
  • Singh P, Nicklin J, Hassall T. Neoadjuvant chemotherapy followed by radical vaginal trachelectomy and adjuvant chemotherapy for clear cell cancer of the cervix: a feasible approach and review. Int j Gynecol Cancer. 2011;21(1):137–140.
  • Jiang X, Jin Y, Li Y, et al. Clear cell carcinoma of the uterine cervix: clinical characteristics and feasibility of fertility-preserving treatment. Onco Targets Ther. 2014;7:111–116.
  • Su Y, Zhang C, Hou W, et al. Fertility-preserving local excision under a hysteroscope with combined chemotherapy in a 6-year-old child with clear cell adenocarcinoma of the cervix: a case report and review of the literature. Medicine. 2020;99(5):e18646.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2020. Fort Washington: National Comprehensive Cancer Network; 2020.
  • Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–104.
  • Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22–36.
  • Bocaneti F, Altamura G, Corteggio A, Velescu E, Borzacchiello G. Expression of bcl-2 and p53 in bovine cutaneous fibropapillomas. Infect Agent Cancer. 2015;10(1):2.
  • Hashiguchi M, Kai K, Nishiyama S, Nakao Y, Yokoyama M, Aishima S. Clear Cell Carcinoma of the Uterine Cervix Presented as a Submucosal Tumor Arising in a Background of Cervical Endometriosis. Int j Gynecol Pathol. 2018;37(1):88–92.
  • Park JY, Kim D, Suh DS, et al. The Role of Laparoscopic Radical Hysterectomy in Early-Stage Adenocarcinoma of the Uterine Cervix. Ann Surg Oncol. 2016;23(Suppl 5):825–833.
  • Thomas MB, Wright JD, Leiser AL, et al. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109(3):335–339.
  • Ueno S, Sudo T, Oka N, et al. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma. Int j Gynecol Cancer. 2013;23(6):1084–1091.
  • Molijn A, Jenkins D, Chen W, et al. The complex relationship between human papillomavirus and cervical adenocarcinoma. Int j Cancer. 2016;138(2):409–416.
  • Kotowicz B, Kaminska J, Fuksiewicz M, et al. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Int j Gynecol Cancer. 2010;20(4):588–592.
  • Kasamatsu T, Onda T, Sawada M, et al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer. 2009;100(9):1400–1405.
  • Zhou L, Sun CT, Lin L, et al. Independent risk factors for ovarian metastases in stage IA-IIB cervical carcinoma. Acta Obstet Gynecol Scand. 2019;98(1):18–23.
  • Zhou J, Chen Y, Zhang P, Lou H. Ovarian preservation in adenocarcinoma of the uterine cervix. J Ovarian Res. 2017;10(1):48.
  • Touhami O, Plante M. Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol. 2015;136(2):384–388.
  • Kim MJ, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Uterine corpus involvement as well as histologic type is an independent predictor of ovarian metastasis in uterine cervical cancer. J Gynecol Oncol. 2008;19(3):181–184.
  • Lee JH, Song JH, Lee SN, et al. Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: the Importance of Patient Selection for the Postoperative Chemoradiotherapy. Cancer Res Treat. 2013;45(1):31–39.